Data from a Phase 2b trial showed that patients with peanut allergy using Viaskin Peanut (DBV Technologies) showed significant improvement using this epicutaneous immunotherapy (EPIT) after one year. The study results were presented at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Houston, TX.
Viaskin Peanut is a patch that utilizes EPIT to dispense small doses of peanut proteins in patients with peanut allergy. In this double-blind, placebo-controlled trial, 221 peanut-allergic children and adults were randomized to receive Viaskin Peanut 50mcg, 100mcg, 250mcg, or placebo for one year. An oral peanut challenge was administered at study entry and at one year to determine their threshold of reactivity.
After one year, 50% of the patients treated with the 250mcg patch were able to tolerate at least 1g of peanut protein (the equivalent of four peanuts), a 10-fold increased in peanut-specific IgG4 levels, an antibody linked to protection after immunotherapy. Children treated with the 250mcg patch experienced a 19-fold increase in these peanut-specific IgG4 levels. No serious adverse events related to the patch treatment were reported.
For more information visit AAAAI.org.